These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
493 related articles for article (PubMed ID: 19690886)
1. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. Yang H; Xiong FX; Lin M; Yang Y; Nie X; Zhou RL J Cancer Res Clin Oncol; 2010 Feb; 136(2):275-81. PubMed ID: 19690886 [TBL] [Abstract][Full Text] [Related]
2. Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients. Yang H; Lin M; Xiong F; Yang Y; Nie X; McNutt MA; Zhou R Surg Today; 2011 Jun; 41(6):810-7. PubMed ID: 21626328 [TBL] [Abstract][Full Text] [Related]
3. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. Yang H; Xiong F; Qi R; Liu Z; Lin M; Rui J; Su J; Zhou R J Surg Oncol; 2010 Apr; 101(5):363-9. PubMed ID: 20358632 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of matrix metalloproteinase-1/ proteinase-activated receptor-1 signaling axis in hepatocellular carcinoma. Liao M; Tong P; Zhao J; Zhang Y; Li Z; Wang J; Feng X; Hu M; Pan Y Pathol Oncol Res; 2012 Apr; 18(2):397-403. PubMed ID: 21909684 [TBL] [Abstract][Full Text] [Related]
5. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis. Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703 [TBL] [Abstract][Full Text] [Related]
6. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer. Xiao M; Jia S; Wang H; Wang J; Huang Y; Li Z J Cancer Res Clin Oncol; 2013 Apr; 139(4):661-7. PubMed ID: 23292099 [TBL] [Abstract][Full Text] [Related]
7. High level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma. Zhu PP; Yuan SG; Liao Y; Qin LL; Liao WJ World J Gastroenterol; 2015 Jun; 21(23):7254-63. PubMed ID: 26109813 [TBL] [Abstract][Full Text] [Related]
8. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer. Meng F; Tan S; Liu T; Song H; Lou G Tumour Biol; 2016 Apr; 37(4):4849-55. PubMed ID: 26526574 [TBL] [Abstract][Full Text] [Related]
9. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer. Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880 [TBL] [Abstract][Full Text] [Related]
10. LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma. Yang H; Zhai G; Ji X; Xiong F; Su J; McNutt MA PLoS One; 2012; 7(4):e34984. PubMed ID: 22509374 [TBL] [Abstract][Full Text] [Related]
11. Low levels of glycoprotein 96 indicate a worse prognosis in early-stage hepatocellular carcinoma patients after hepatectomy. Ji F; Zhang Y; Zhu ZB; Guo Y; Shen SL; Cao QH; Li SQ; Peng BG; Liang LJ; Hua YP Hum Pathol; 2019 Apr; 86():193-202. PubMed ID: 30529751 [TBL] [Abstract][Full Text] [Related]
12. [A new prognostic score system of hepatocellular carcinoma following hepatectomy]. Wang YK; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Li MX; Chen X; Wu XL; Mao R; Hu XH; Hu HJ; Liu JM; Cai JQ Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):903-909. PubMed ID: 29262506 [No Abstract] [Full Text] [Related]
13. C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion. Kim JM; Kwon CH; Joh JW; Ko JS; Park JB; Lee JH; Kim SJ; Paik SW; Park CK World J Surg Oncol; 2013 Apr; 11():92. PubMed ID: 23618082 [TBL] [Abstract][Full Text] [Related]
14. Lysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for gastric carcinoma. Liu L; Xu X; Jing L; Zhou G; Cao Z; Han Y; Zhou R PLoS One; 2015; 10(2):e0118026. PubMed ID: 25689860 [TBL] [Abstract][Full Text] [Related]
16. Low expression of organic anion-transporting polypeptide 1B3 predicts a poor prognosis in hepatocellular carcinoma. Chen S; Li K; Jiang J; Wang X; Chai Y; Zhang C; Deng Q; Shuai L; Feng K; Ma K; Zhang L World J Surg Oncol; 2020 Jun; 18(1):127. PubMed ID: 32534581 [TBL] [Abstract][Full Text] [Related]
17. Fidgetin as a potential prognostic biomarker for hepatocellular carcinoma. Zhou B; Wang J; Gao J; Xie J; Chen Y Int J Med Sci; 2020; 17(17):2888-2894. PubMed ID: 33162817 [No Abstract] [Full Text] [Related]
18. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Hyeon J; Ahn S; Lee JJ; Song DH; Park CK Dig Dis Sci; 2013 Jul; 58(7):1916-22. PubMed ID: 23456506 [TBL] [Abstract][Full Text] [Related]
19. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma. Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591 [TBL] [Abstract][Full Text] [Related]
20. High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection. Ding X; Wang K; Wang H; Zhang G; Liu Y; Yang Q; Chen W; Hu S J Gastrointest Surg; 2012 Apr; 16(4):828-36. PubMed ID: 22072303 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]